MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/jce.15742

Медицинская библиотека · Journal of cardiovascular electrophysiology · 2022

Contact force catheter ablation for the treatment of persistent atrial fibrillation: Results from the PERSIST-END study.

Lo Monica, Nair Devi, Mansour Moussa, Calkins Hugh, Reddy Vivek Y, Colley B Judson, Tanaka-Esposito Christine, Sundaram Sri, DeLurgio David B, Sanders Prashanthan, Khatib Sammy, Bernard Michael, Olson Nicholas, Gibson Douglas, Miller Amber, Li Jingyun, Natale Andrea

Многоцентровое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

INTRODUCTION

Use of a novel magnetic sensor enabled optical contact force ablation catheter has been established to be safe and effective for treatment of symptomatic drug-refractory paroxysmal atrial fibrillation (AF) but has yet to be demonstrated in the persistent AF (PersAF) population.

METHODS

PERSIST-END was a multicenter, prospective, nonrandomized, investigational study designed to demonstrate the safety and effectiveness of TactiCath™ Ablation Catheter, Sensor Enabled™(SE) (TactiCath SE) for use in the treatment of subjects with documented PersAF refractory or intolerant to at least one Class I/III AAD. The ablation strategy included pulmonary vein isolation and additional targets at physician discretion. Follow-up through 15-months, including a 3-month blanking period and 3-month therapy consolidation period, was performed with cardiac event and Holter monitoring. Primary safety, primary effectiveness, clinical success, and quality of life (QOL) endpoints were analyzed.

RESULTS

Of 224 subjects enrolled at 21 investigational sites in the United States and Australia, 223 underwent ablation with the investigational catheter. The primary safety event rate was 3.1% (seven events in seven subjects). The Kaplan-Meier estimate of freedom from AF/atrial flutter/atrial tachycardia recurrence at 15-months was 61.6% and clinical success at 15 months was 89.8%. Subject QOL significantly improved following ablation as assessed via AFEQT (31.6 point increase, p < .0001) and EQ-5D-5L (10.7 point increase, p < .0001) and was met with a 53% reduction in all cause cardiovascular healthcare utilization.

CONCLUSION

The sensor-enabled force-sensing catheter is safe and effective for the treatment of drug refractory recurrent symptomatic PersAF, reducing arrhythmia recurrence while improving QOL and healthcare utilization.

Для цитирования: Lo Monica, Nair Devi, Mansour Moussa, Calkins Hugh, Reddy Vivek Y, Colley B Judson, Tanaka-Esposito Christine, Sundaram Sri, DeLurgio David B, Sanders Prashanthan, Khatib Sammy, Bernard Michael, Olson Nicholas, Gibson Douglas, Miller Amber, Li Jingyun, Natale Andrea. Contact force catheter ablation for the treatment of persistent atrial fibrillation: Results from the PERSIST-END study.. Journal of cardiovascular electrophysiology. 2022. DOI: 10.1111/jce.15742.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.